Braveheart Bio, Inc. Statistics
Braveheart Bio, Inc. (BRVE) Stock Statistics & Valuation Metrics
Total Valuation
Braveheart Bio, Inc. has a market cap or net worth of $1.69B. The enterprise value is $1.31B.
- Market Cap
- $1.69B
- Enterprise Value
- $1.31B
Share Statistics
Braveheart Bio, Inc. has 89,870,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 89,870,350
- Owned by Insiders
- 57.00%
- Owned by Institutions
- 10.15%
Financial Efficiency
Braveheart Bio, Inc.’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -79.36%.
- Return on Equity (ROE)
- -0.79
- Return on Assets (ROA)
- -0.75
- Return on Invested Capital (ROIC)
- -79.36%
- Return on Capital Employed (ROCE)
- -0.79
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.36M
- Employee Count
- 49
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Braveheart Bio, Inc. is -6.39. Braveheart Bio, Inc.’s PEG ratio is 0.20.
- PE Ratio
- -6.39
- PS Ratio
- 0.00
- PB Ratio
- 1.93
- Price to FCF
- -26.84
- Price to Operating Cash Flow
- -20.15
- PEG Ratio
- 0.20
Income Statement
In the last 12 months, Braveheart Bio, Inc. had revenue of 0 and earned -66.75M in profits. Earnings per share was -5.32.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -66.75M
- Pretax Income
- -66.75M
- Net Income
- -66.75M
- EBITDA
- -66.75M
- Earnings Per Share (EPS)
- -5.32
Cash Flow
In the last 12 months, operating cash flow was -47.78M and capital expenditures -863,000, giving a free cash flow of -48.65M billion.
- Operating Cash Flow
- -47.78M
- Free Cash Flow
- -48.65M
- Free Cash Flow per Share
- -0.93
Dividends & Yields
Braveheart Bio, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.80%
- Earnings Yield
- -6.60%
Stock Price Statistics
- Beta
- -0.04
- 52-Week Price Change
- -36.98%
- 50-Day Moving Average
- 22.07
- 200-Day Moving Average
- 23.66
- Relative Strength Index (RSI)
- 41.23
- Average Volume (3m)
- 460.31K
Important Dates
Braveheart Bio, Inc. upcoming earnings date is ―, After Close (Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Braveheart Bio, Inc. as a current ratio of 17.03, with Debt / Equity ratio of 0.00%
- Current Ratio
- 17.03
- Quick Ratio
- 17.03
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.34
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Braveheart Bio, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Braveheart Bio, Inc. EV to EBITDA ratio is -17.07, with an EV/FCF ratio of -23.81.
- EV to Sales
- 0.00
- EV to EBITDA
- -17.07
- EV to Free Cash Flow
- -23.81
- EV to Operating Cash Flow
- -24.24
Balance Sheet
Braveheart Bio, Inc. has $349.27M in cash and marketable securities with $515.00K in debt, giving a net cash position of $348.76M billion.
- Cash & Marketable Securities
- $349.27M
- Total Debt
- $515.00K
- Net Cash
- $348.76M
- Net Cash Per Share
- $3.88
- Tangible Book Value Per Share
- $9.55
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Braveheart Bio, Inc. is $45.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $45.50
- Price Target Upside
- 142.28% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- ―

